Pharmacology and Drug Interactions

Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.

7 care stages · 29 guidelines · 0 courses · 0 providers

Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.

6 care stages · 13 guidelines · 0 courses · 0 providers

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

2 care stages · 7 guidelines · 0 courses · 0 providers

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

4 care stages · 6 guidelines · 0 courses · 0 providers

Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.

5 care stages · 5 guidelines · 1 courses · 1 providers

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

6 care stages · 5 guidelines · 0 courses · 0 providers

Competent facilitation requires practical knowledge of dosage ranges, initial dosing, boosters, formulation handling, and administration errors. The handbook stresses both clinical judgment and meticulous procedural care.

3 care stages · 4 guidelines · 0 courses · 0 providers

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

4 care stages · 3 guidelines · 0 courses · 0 providers

Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.

5 care stages · 3 guidelines · 0 courses · 0 providers

Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.

2 care stages · 2 guidelines · 0 courses · 0 providers

Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.

4 care stages · 1 guidelines · 2 courses · 2 providers

Ability to correctly deliver the investigational inhaled drug using standardized vaporization procedures and participant instructions. Safe and accurate administration is central to the dosing protocol.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the proposed mechanisms, phases of effect, and common subjective and physical effects of ibogaine relevant to clinical supervision. This knowledge informs safe monitoring and therapeutic pacing.

3 care stages · 1 guidelines · 0 courses · 0 providers

The therapist/facilitator must understand potential drug-interaction concerns and formulation-related differences that could alter tolerability or safety. The source mentions caution with antiemetics and alternative preparations.

3 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

4 care stages · 1 guidelines · 0 courses · 0 providers

Providers must know that ibogaine does not treat benzodiazepine withdrawal and that sudden cessation can be dangerous. Benzodiazepine-dependent patients should not be told to stop abruptly.

1 care stage · 1 guidelines · 0 courses · 0 providers

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

3 care stages · 1 guidelines · 0 courses · 0 providers

Use pharmacogenetic information to anticipate altered ibogaine metabolism and exposure. The study identifies CYP2D6 activity as a major determinant of ibogaine clearance.

1 care stage · 1 guidelines · 0 courses · 0 providers

Tracks dose-dependent changes without assuming full psychedelic effects. This includes recognizing that low-dose exposure may modulate brain activity while remaining sub-psychedelic.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the role of serotonergic mechanisms and the implications of receptor antagonism for acute psychedelic effects. Use this knowledge to interpret responses and co-administration effects.

2 care stages · 1 guidelines · 0 courses · 0 providers

Knows the purpose and indications of medications maintained for side effect management or emergency use during KAP. Can explain how these medications relate to specific risks.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.

2 care stages · 1 guidelines · 0 courses · 0 providers

Knows the use of ibogaine as a detoxification agent in medical and nonmedical settings and understands that its mechanism of action is novel and not fully established.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the basic rationale for ibogaine’s proposed effects in substance use disorders. This includes its reported ability to ease withdrawal, reduce craving, and act through multiple neurotransmitter systems.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators should understand the therapeutic and adverse-effect context of psilocybin and comparator antidepressant treatment, since the trial directly compared psilocybin with escitalopram.

1 care stage · 1 guidelines · 0 courses · 0 providers

Recognizes medical factors that may increase risk during inhaled 5-MeO-DMT administration. Medical clearance is required before dosing.

4 care stages · 1 guidelines · 0 courses · 0 providers

Identify concurrent medications or recent drug exposures that may interact dangerously with ibogaine. The clinician/facilitator must understand that ibogaine can potentiate other drugs and that certain psychiatric medications or toxic agents may contraindicate treatment.

1 care stage · 1 guidelines · 0 courses · 0 providers

Screen for co-medications that may prolong QTc or affect CYP2D6 metabolism. This is critical to reduce confounding and prevent additive toxicity.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists must understand clinically significant drug interactions with ibogaine, including QT-prolonging, serotonergic, centrally acting, and CYP2D6-related medications. This knowledge informs screening, tapering, and dosing decisions.

3 care stages · 1 guidelines · 0 courses · 0 providers

Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.

2 care stages · 1 guidelines · 0 courses · 0 providers

Prepare participants to correctly use nicotine replacement therapy when assigned to the control arm. Facilitators must provide education, dosing instructions, and side-effect guidance.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understands core pharmacokinetic concepts needed to interpret study findings and guide safety observation. Recognizes dose-linear exposure changes and elimination characteristics relevant to monitoring windows.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understand ibogaine, noribogaine, and noribogaine glucuronide disposition and how exposure relates to clinical effects. This knowledge supports safe interpretation of observed toxicity and response.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the pharmacology and interaction risks of 5-MeO-DMT/BPL-003, including serotonergic and cardiovascular concerns. This knowledge informs safe preparation, exclusion screening, and monitoring.

4 care stages · 1 guidelines · 0 courses · 0 providers

Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need knowledge of conditions and medications that may make 5-MeO-DMT unsafe or inappropriate. They should identify possible interactions and discuss them clearly before participation.

2 care stages · 1 guidelines · 0 courses · 0 providers

The facilitator should understand the administration context for the intervention. The source highlights inhalation as the studied route and its rapid onset.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need working knowledge of administration routes because onset, duration, intensity, and tolerability vary substantially. This informs preparation, monitoring, and participant education.

3 care stages · 1 guidelines · 0 courses · 0 providers

Recognize when post-session exhaustion or discomfort may warrant supportive symptom management and understand the limited use of sedatives in the protocol. The facilitator must balance comfort with safety and document any sedating agents used.

1 care stage · 1 guidelines · 0 courses · 0 providers

Administers repeated sublingual microdoses of 5-MeO-DMT in a controlled clinical trial setting. Must follow the assigned dose schedule and maintain blinding across active and placebo conditions.

1 care stage · 1 guidelines · 0 courses · 0 providers

Know that ayahuasca composition can vary and that chemical characterization matters. Facilitators or clinical teams should understand the potency and stability of the administered brew.

2 care stages · 1 guidelines · 0 courses · 0 providers

The intervention involved two dosing sessions with either low-dose or high-dose LSD, implying facilitators need knowledge of session-based LSD administration frameworks. This includes understanding that psychotherapy support is paired with specified dosing regimens.

1 care stage · 1 guidelines · 0 courses · 0 providers

Recognize that current evidence does not establish the lowest effective or safest exposure for ibogaine. Facilitators must understand the uncertainty surrounding efficacy at reduced doses.

2 care stages · 1 guidelines · 0 courses · 0 providers

Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.

6 care stages · 0 guidelines · 2 courses · 1 providers

The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.

3 care stages · 0 guidelines · 1 courses · 1 providers

Learners are taught to design custom protocols for both microdosing and macrodosing based on client goals. The page also references microdosing formulas and practical application of timing and dosage nuances.

4 care stages · 0 guidelines · 1 courses · 1 providers

Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.

3 care stages · 6 guidelines · 0 courses · 0 providers

Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.

8 care stages · 5 guidelines · 2 courses · 2 providers

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

3 care stages · 3 guidelines · 0 courses · 0 providers

Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

3 care stages · 2 guidelines · 0 courses · 0 providers

Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.

3 care stages · 2 guidelines · 0 courses · 0 providers

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

3 care stages · 1 guidelines · 0 courses · 0 providers

Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

1 care stage · 1 guidelines · 0 courses · 0 providers

Knows the conditions that may disqualify a person from ketamine treatment and can apply that knowledge during screening. Recognizes medical, psychiatric, pregnancy-related, and substance-related contraindications.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ability to administer LSD in a psychotherapy setting using the regimen described in the source. The therapist/facilitator must understand session-based dosing and treatment course structure.

1 care stage · 1 guidelines · 0 courses · 0 providers

Respond promptly to complications arising during ibogaine-supported detoxification. Facilitators need a clear escalation plan for QTc prolongation and intolerable withdrawal.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

3 care stages · 1 guidelines · 0 courses · 0 providers

Support patients through acute opioid withdrawal during ibogaine treatment when withdrawal symptoms are present. The source describes use of oral hydromorphone for symptom relief within the protocol.

1 care stage · 1 guidelines · 0 courses · 0 providers

The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.

6 care stages · 0 guidelines · 1 courses · 1 providers